Precision medicine in pediatric oncology
暂无分享,去创建一个
[1] Sven Rahmann,et al. Mutational dynamics between primary and relapse neuroblastomas , 2015, Nature Genetics.
[2] Toshihiro Kumabe,et al. Cytogenetic prognostication within medulloblastoma subgroups. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[4] Qing-Rong Chen,et al. A Children's Oncology Group and TARGET Initiative Exploring the Genetic Landscape of Wilms Tumor , 2017, Nature Genetics.
[5] A. Jemal,et al. Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.
[6] Li Ding,et al. The Pediatric Cancer Genome Project , 2012, Nature Genetics.
[7] Gudrun Schleiermacher,et al. Implementation of mechanism of action biology-driven early drug development for children with cancer. , 2016, European journal of cancer.
[8] Stuart J. Andrews,et al. Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations , 2016, Genome Medicine.
[9] B. Crompton,et al. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. , 2016, JAMA oncology.
[10] J. Maris,et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. , 2013, The Lancet. Oncology.
[11] Steven J. M. Jones,et al. Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways. , 2016, Cancer cell.
[12] Jonathan M Marron,et al. Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience , 2016, Pediatric blood & cancer.
[13] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[14] P. Raman,et al. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome , 2016, PLoS genetics.
[15] Gudrun Schleiermacher,et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations , 2015, Nature Genetics.
[16] G. Caponigro,et al. Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma , 2016, Clinical Cancer Research.
[17] J. Biegel,et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. , 2010, Neuro-oncology.
[18] Tao Wang,et al. Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.
[19] Caroline McNeil,et al. NCI-MATCH launch highlights new trial design in precision-medicine era. , 2015, Journal of the National Cancer Institute.
[20] Nallasivam Palanisamy,et al. Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. , 2015, JAMA.
[21] M. Schrappe,et al. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. , 2015, European journal of cancer.
[22] Rebecca L. Siegel Mph,et al. Cancer statistics, 2016 , 2016 .
[23] A. Chinnaiyan,et al. Precision medicine in pediatric oncology: Lessons learned and next steps , 2017, Pediatric blood & cancer.
[24] M. Harris,et al. Future of clinical genomics in pediatric oncology. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Roland Eils,et al. The whole-genome landscape of medulloblastoma subtypes , 2017, Nature.
[26] P. Nathan,et al. Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. , 2016, The New England journal of medicine.
[27] M. Lim,et al. Target and Agent Prioritization for the Children’s Oncology Group—National Cancer Institute Pediatric MATCH Trial , 2017, Journal of the National Cancer Institute.
[28] S. Hunger,et al. Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics , 2017, British journal of haematology.
[29] C. Mullighan,et al. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. , 2017, Blood.
[30] Heather L. Mulder,et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.
[31] F. Speleman,et al. Emergence of new ALK mutations at relapse of neuroblastoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] G. Reaman,et al. Enrolling Adolescents in Disease/Target-Appropriate Adult Oncology Clinical Trials of Investigational Agents , 2016, Clinical Cancer Research.
[33] David T. W. Jones,et al. Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. , 2016, European journal of cancer.
[34] Edward S. Kim,et al. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[36] P. Varlet,et al. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial , 2017, Clinical Cancer Research.
[37] M. Loh,et al. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. , 2017, Blood.
[38] Steven J. M. Jones,et al. The genetic landscape of high-risk neuroblastoma , 2013, Nature Genetics.
[39] M. Konopleva,et al. Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype. , 2017, Clinical advances in hematology & oncology : H&O.
[40] Yoon-Jae Cho,et al. Pediatric oncology enters an era of precision medicine. , 2017, Current problems in cancer.
[41] S. Pfister,et al. Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective , 2017, Nature Reviews Clinical Oncology.
[42] Lisa McShane,et al. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[43] Sumithra J Mandrekar,et al. Precision oncology: A new era of cancer clinical trials. , 2017, Cancer letters.
[44] W. Evans,et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.
[45] M. Loh,et al. Precision Medicine in Pediatric Oncology: Translating Genomic Discoveries into Optimized Therapies , 2017, Clinical Cancer Research.
[46] O. Delattre,et al. Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors , 2017, Pediatric blood & cancer.
[47] M. Loh,et al. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. , 2013, Blood.
[48] A. Chen,et al. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH. , 2017, Current problems in cancer.
[49] K. Janeway. Molecular profiling in the clinic: Moving from feasibility assessment to evaluating clinical impact , 2017, Pediatric blood & cancer.
[50] Asher Mullard,et al. NCI-MATCH trial pushes cancer umbrella trial paradigm , 2015, Nature Reviews Drug Discovery.